Revvity, Inc.
Every calculator, already run for RVTY
Open the full toolkit →You have the numbers on RVTY. Get the argument.
A written report on which of these readings actually decide the outcome for Revvity, Inc., what has to stay true for the price to work, and the specific thing that would break it. The first one is free.
Key market data
Analyst consensus
19 analysts covering RVTYAnalyst Price Target Disagreement for Revvity, Inc.
Wall Street's bull case implies +15% from the current price; the bear case implies -23%. A 38% spread signals high analyst disagreement — run your own DCF to anchor on fundamentals rather than street consensus.
Ownership & short interest
Insider Trading Activity for RVTY
| Insider | Role | Type | Shares | Price | Value | Date | Filing |
|---|---|---|---|---|---|---|---|
About Revvity, Inc.
Revvity, Inc. provides health sciences solutions, technologies, and services. The company offers instruments, reagents, software, subscriptions, detection and imaging technologies, extended warranties, training and services; and instruments, reagents, assay platforms and software products for early detection of common and rare conditions, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its products are used for testing and screening genetic abnormalities, disorders, and diseases, including down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. The company also develops technologies that enable…
RVTY — frequently asked
Is RVTY a buy right now?
Wall Street's consensus rating on Revvity, Inc. is Buy across 19 analysts, with a mean price target of $128.47 (-11% vs. the current $143.59). Ratings are a starting point — run the DCF and check the financial-health readings above before deciding.
Is RVTY overvalued?
RVTY trades at 69.0x trailing earnings, against a DCF fair value of $116 per share. The current price implies 9% annual free-cash-flow growth for a decade. Open the DCF or reverse-DCF tool to change the assumptions and see the range.
When is RVTY's next earnings date?
Revvity, Inc. is next scheduled to report earnings around Oct 26, 2026. A full RVTY research report from Basis Report covers the setup into that print — estimates, the beat/miss record, and what would move the thesis.
What is the analyst price target disagreement for Revvity, Inc.?
Analysts covering Revvity, Inc. (RVTY) range from a bear-case target of $110.00 to a bull-case high of $165.00, with a mean consensus target of $128.47 across 17 analysts. The spread of $55.00 (38% of the current price) indicates high disagreement on the outlook. Run the DCF calculator to build your own estimate independent of street consensus.
Compare Revvity, Inc. against related stocks
Explore additional stock overview pages and jump directly into full report generation for each symbol.
Sector peers
Most-followed names in the same sector.
Nearby tickers
Additional public equities from our tracked universe.
Market leaders
Large-cap symbols investors frequently compare.
Investor Guides For Revvity, Inc.
Start with the evergreen guides that matter most for Healthcare, then move back into the ticker page when you want to pressure-test the framework on a live name.
Generate your full RVTY research report
DCF model, five-year financials, moat assessment, a BUY/HOLD/SELL rating, and the risks that matter — on Revvity, Inc., in minutes. 3 free reports included with every account — no credit card required.